Archivio istituzionale della ricerca dell'Università degli Studi di Palermo

SERRETTA, Vincenzo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 12.586
EU - Europa 6.822
AS - Asia 2.225
AF - Africa 79
SA - Sud America 30
OC - Oceania 24
Continente sconosciuto - Info sul continente non disponibili 7
Totale 21.773
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.563
IT - Italia 1.807
CN - Cina 1.165
FI - Finlandia 1.046
UA - Ucraina 965
SG - Singapore 792
RU - Federazione Russa 664
DE - Germania 592
IE - Irlanda 569
SE - Svezia 359
GB - Regno Unito 336
FR - Francia 149
BE - Belgio 96
RO - Romania 93
IN - India 77
CI - Costa d'Avorio 64
KR - Corea 59
CH - Svizzera 36
NL - Olanda 31
HK - Hong Kong 23
JP - Giappone 22
AU - Australia 19
CA - Canada 19
BR - Brasile 17
CZ - Repubblica Ceca 14
TR - Turchia 13
PL - Polonia 12
IR - Iran 11
AT - Austria 10
GR - Grecia 10
ES - Italia 9
IL - Israele 8
EU - Europa 6
ID - Indonesia 6
KW - Kuwait 6
LB - Libano 5
NZ - Nuova Zelanda 5
TW - Taiwan 5
UZ - Uzbekistan 5
AR - Argentina 4
BD - Bangladesh 4
EG - Egitto 4
LT - Lituania 4
AL - Albania 3
BG - Bulgaria 3
CL - Cile 3
CO - Colombia 3
MX - Messico 3
PK - Pakistan 3
PT - Portogallo 3
SA - Arabia Saudita 3
SD - Sudan 3
ZA - Sudafrica 3
AM - Armenia 2
CM - Camerun 2
DK - Danimarca 2
EC - Ecuador 2
GE - Georgia 2
MD - Moldavia 2
MN - Mongolia 2
PH - Filippine 2
RS - Serbia 2
TH - Thailandia 2
VN - Vietnam 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AZ - Azerbaigian 1
BH - Bahrain 1
BT - Bhutan 1
EE - Estonia 1
KH - Cambogia 1
LU - Lussemburgo 1
LY - Libia 1
ME - Montenegro 1
MY - Malesia 1
NG - Nigeria 1
NO - Norvegia 1
OM - Oman 1
PA - Panama 1
PY - Paraguay 1
SK - Slovacchia (Repubblica Slovacca) 1
TN - Tunisia 1
Totale 21.773
Salva come PNG Salva come JPEG
Città #
Fairfield 1.631
Ashburn 1.161
Chandler 1.084
Woodbridge 867
Wilmington 821
Ann Arbor 759
Houston 680
Seattle 625
Singapore 623
Dublin 567
Jacksonville 526
Cambridge 515
Medford 413
Nanjing 275
Des Moines 267
Princeton 265
Palermo 172
Altamura 171
Boardman 149
Tulsa 148
Lawrence 137
New York 126
Dearborn 122
Beijing 112
Nanchang 108
San Diego 106
Helsinki 104
Brussels 95
Shenyang 91
Milan 81
Hebei 73
Abidjan 64
Changsha 63
Jiaxing 62
Ludwigshafen am Rhein 61
Santa Clara 60
Tianjin 60
Seongnam 46
Jinan 44
Kumar 43
Saint Petersburg 43
Verona 39
Redwood City 37
Munich 36
Bremen 34
Venice 34
Nave 33
Rome 33
London 32
Auburn Hills 30
Zhengzhou 30
Falls Church 26
Guangzhou 26
San Mateo 26
Ningbo 25
San Paolo di Civitate 25
Washington 22
Columbus 19
Lanzhou 19
Taizhou 18
Hangzhou 17
Kunming 17
Los Angeles 17
Napoli 17
Norwalk 16
Dallas 15
Düsseldorf 14
Falkenstein 13
Taiyuan 13
Buccinasco 12
Edinburgh 12
Hefei 12
Orange 12
Mountain View 11
Nuremberg 11
Pune 11
Catania 10
Chicago 10
Haikou 10
Indiana 10
Brno 9
Central District 9
Frankfurt am Main 9
Paris 9
Phoenix 9
Redmond 9
Tokyo 9
Bologna 7
Den Haag 7
Kilburn 7
San Francisco 7
Seoul 7
Springfield 7
Sydney 7
Yellow Springs 7
Amsterdam 6
Berlin 6
Central 6
Hong Kong 6
Moscow 6
Totale 14.373
Salva come PNG Salva come JPEG
Nome #
S9-Fibronectin, EGF-R, HB-EGF:biomarkers of urothelial damage during intravesical adjuvant therapy? 515
Characterization of human infiltrating and circulating gamma-delta t cells in prostate cancer 220
Manuale di Urologia e Andrologia. Capitolo 1: Anatomia dell'apparato genito-urinario 194
Clinical and biochemical markers of visceral adipose tissue activity: Body mass index, visceral adiposity index, leptin, adiponectin, and matrix metalloproteinase-3. Correlation with Gleason patterns 4 and 5 at prostate biopsy 192
Prospective, randomized, crossover comparison of sublingual apomorphine (3 mg) with oral sildenafil (50 mg) for male erectile dysfunction. 188
Whatsapp messenger as a tool for the multidisciplinary management in everyday clinical practice 181
Cytokine gene expression in the tunica albuginea 
of patients with Peyronie’s disease. Pilot study with 
a control group 177
Intravesical chemotherapy for intermediate risk non-muscle invasive bladder cancer recurring after a first cycle of intravesical adjuvant therapy 172
Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer Patients Progressing after Docetaxel: A Prospective Single-Center Study 171
Drinking water source and cigarette smoking in transitional cell carcinoma of the bladder. 161
Correlation between GP-170 expression, prognosis, and chemoresistance of superficial bladder carcinoma 158
A 1-year maintenance after early adjuvant intravesical chemotherapy has a limited efficacy in preventing recurrence of intermediate risk non-muscle-invasive bladder cancer. 156
Segmental resection of distal ureter with termino-terminal ureteric anastomosis vs bladder cuff removal and ureteric re-implantation for upper tract urothelial carcinoma: results of a multicentre study 153
Sarcomatoid carcinoma of urinary bladder: Immunohistochemical study of an uncommon case 149
Preliminary report of a multicentric study on environmental risk factors in Ta-T1 transitional cell carcinoma of the bladder 145
A phase I-II study on intravesical Gemcitabine in superficial bladder papillary tumors 142
Hypofractionated postoperative helical tomotherapy in prostate cancer: a mono-institutional report of toxicity and clinical outcomes 141
Carcinoma uroteliale in cisti pielogena 140
Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder 139
PROSPECTIVE, RANDOMIZED, CROSSOVER COMPARISON OF SUBLINGUAL APOMORPHINE (3 mg) WITH ORAL SILDENAFIL (50 mg) FOR MALE ERECTILE DYSFUNCTION 137
Does the Compliance to Intravesical BCG Differ between Common Clinical Practice and International Multicentric Trials? 137
Modificazioni del PSA dopo terapia antibiotica in pazienti candidati alla biopsia prostatica. 136
PSA reduction (after antibiotics) permits to avoid or postpone prostate biopsy in selected patients 136
Multiplicity and history have a detrimental effect on survival in patients with T1G3 bladder tumors selected for conservative treatment. 134
Cytokines gene expression in the tunica albuginea of patients with Peyronie’s disease. Pilot study with a control group 133
Il carcinoma prostatico in Calabria e Sicilia. 131
Gemcitabine in intravesical treatment of Ta-T1 transitional cell carcinoma of the bladder: Phase I-II study on marker lesions 128
Clinical implications of a rare renal entity: Pleomorphic Hyalinizing Angiectatic Tumor (PHAT) 128
The activity of intravesical hyaluronic acid and chondroitin sulfate administration on urothelial gene expression. Preliminary results on the epidermal growth factor receptor and fibronectin gene expression evaluated in bladder washings of patients affected by non muscle-invasive bladder cancer 123
Re: Urinary pH is Highly Associated With Tumor Recurrence During Intravesical Mitomycin C Therapy for Nonmuscle Invasive Bladder Tumor 122
Although rare, severe complications following intravesical bacillus Calmette-Guerin treatment should not be overlooked! 122
T1HG Bladder Tumours: So Many Papers, Do We Need Them? Yes, We Do! 120
Randomized Phase II trial assessing estramustine and vinblastine combination chemotherapy vs estramustine alone in patients with progressive hormone-escaped metastatic prostate cancer 119
Mitomycin C from birth to adulthood 119
Distribution of smoking, water resource and other environmental factors in patients affected by superficial bladder cancer 118
Prognostic Factors and Risk Groups in T1G3 Non–Muscle-invasive Bladder Cancer Patients Initially Treated with Bacillus Calmette-Gue´ rin: Results of a retrospective Multicenter Study of 2451 Patients 116
Cytokines gene expression in the tunica albuginea in patients with Peyronie’s disease. Pilot study with a control group 114
Does Exist A Correlation Between BMI and Gleason Patterns 4 and 5 At Prostate Biopsy? 114
PSA and second-line therapy of hormone refractory prostate carcinoma 114
An increased body mass index is associated with a worse prognosis in patients administered BCG immunotherapy for T1 bladder cancer 114
Intravesical gemcitabine in superficial bladder tumours preliminary results of a phase I-II study 113
WHATSAPP MESSENGER AS A REAL-TIME TOOL FOR A LONG-DISTANCE ACTIVITY OF A MULTIDISCIPLINARY 113
Epidermal Growth Factor Receptor (EGFR) Cell Expression During Adjuvant Treatment After Transurethral Resection for Non-Muscle-Invasive Bladder Cancer: A New Potential Tool to Identify Patients at Higher Risk of Disease Progression 113
Segmental ureterectomy vs. radical nephroureterectomy for ureteral carcinoma in patients with a preoperative glomerular filtration rate less than 90 ml/min/1.73 m2: A multicenter study 113
PROGNOSTIC FACTORS AND RISK GROUPS IN T1G3 PATIENTS INITIALLY TREATED WITH BCG: RESULTS OF A MULTICENTER RETROSPECTIVE SERIES IN 2530 PATIENTS 112
The impact of re-transurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high-grade/Grade 3 bladder cancer treated with bacille Calmette-Guérin 112
The efficacy of BCG TICE and BCG Connaught in a cohort of 2,099 patients with T1G3 non-muscle-invasive bladder cancer 111
INTRAVESICAL GEMCITABINE IN SUPERFICIAL BLADDER TUMOURS.RESULTS OF A PHASE I-II STUDY 110
Studio pilota sul valore predittivo dei livelli plasmatici di 9 fattori angiogenetici nella selezione di pazienti candidati alla biopsia prostatica 110
A randomized trial comparing tamoxifen therapy vs. tamoxifen prophylaxis in bicalutamide-induced gynecomastia. 110
Validation of Neutrophil-to-lymphocyte Ratio in a Multi-institutional Cohort of Patients With T1G3 Non-muscle-invasive Bladder Cancer 110
Genitourinary Symptoms-Patient Help-Seeking and General Practitioner Management: An Outpatient Based Survey at a Tertiary Hospital in Southern Italy 109
Analisi preliminare dei fattori demografici ed eziopatogenetici in pazienti affetti da carcinoma vescicale a medio rischio di recidiva 108
High-Grade T1 on Re-Transurethral Resection after Initial High-Grade T1 Confers Worse Oncological Outcomes: Results of a Multi-Institutional Study 108
The clinical value of PSA increase during intravesical adjuvant therapy for nonmuscle-invasive bladder cancer. 107
Cigarette smoking and drinking water source: Correlation with clinical features and pathology of superficial bladder carcinoma. 106
Moderate hypofractionated helical tomotherapy for prostate cancer in a cohort of older patients: a mono-institutional report of toxicity and clinical outcomes 106
Oral chemotherapy in hormone-refractory prostate carcinoma patients unwilling to be admitted to hospital 106
Ruolo prognostico della p53 nel tumore vescicale superficiale. Correlazione con recidiva e progressione – 105
TERAPIA CONSERVATIVA DELL'UROTELIOMA VESCICALE T1G3. RISULTATI SU 235 PAZIENTI 105
Are referral centers for non-muscle-invasive bladder cancer compliant to EAU guidelines? A report from the vesical antiblastic therapy Italian study 105
Valore clinico della riduzione del PSA in soggetti candidati all’agobiopsia prostatica 104
Cigarette Smoking Status at Diagnosis and Recurrence in Intermediate-risk Nonemuscle-invasive Bladder Carcinoma 104
POSITIVITA’ DELL’NMP22 E NEGATIVITA’ CISTOSCOPICA E CITOLOGICA. QUALE SIGNIFICATO ATTRIBUIRE? 103
Environmental factors in superficial bladder cancer. Preliminary report of a prospective study 103
Impact of stage migration on bladder cancer: A slow but steady improvement in the long term survival rates after radical cystectomy in the last 25 years 103
The fate of patients with locally advanced bladder cancer treated conservatively with neoadjuvant chemotherapy, extensive transurethral resection and radiotherapy: 10-year experience 103
Variability in the Performance of Nuclear Matrix Protein 22 for the Detection of Bladder Cancer 102
Clinical pitfalls in diagnosis of nonmuscle-invasive bladder cancer 102
Modified Glasgow prognostic score is associated with risk of recurrence in bladder cancer patients after radical Cystectomy: A multicenter experience 102
The Clinical Use of Statistical Permutation Test Methodology: A Tool for Identifying Predictive Variables of Outcome 101
Systemic Inflammatory Markers and Oncologic Outcomes in Patients with High-risk Non-muscle-invasive Urothelial Bladder Cancer 101
Potential Effect of Antiplatelet and Anticoagulant Therapy on the Timing of the Diagnosis of Bladder Cancer 100
Significato clinico della positività della NMP22 in pazienti in follow-up per carcinoma vescicale superficiale. Risultati a lungo termine 99
PROSTATA (PROSTATITI, IPERTROFIA PROSTATICA, CANCRO DELLA PROSTATA) 99
Salvage Therapy With Oral Metronomic Cyclophosphamide and Methotrexate for Castration refractory Metastatic Adenocarcinoma of the Prostate Resistant to Docetaxel 99
Postoperative nomogram for invasive bladder cancer: Does it really work? A multicenter cohort study 99
Is there a role for recombinant tumor necrosis factor alpha in the intravesical treatment of superficial bladder tumors?--a phase II study 99
Studio randomizzato sul ruolo del mantenimento nella chemioprofilassi endovescicale precoce dopo TUR con Epirubicina. XVI Congresso Nazionale Società Italiana di Urologia Oncologica. 30 Novembre - 3 Dicembre 2006. Arch. Ital. Urol. Androl. vol. , pp. 71. ISBN/ISSN: 1124-3562. 97
Attività lavorativa e fattori di rischio ambientale in pazienti affetti da carcinoma vescicale superficiale. 97
Correlation between BMI and the pathological features of prostate cancer at biopsy 97
Intravesical gemcitabine is superficial bladder tumours. Results of a phase I-II study 96
How Can the COVID-19 Pandemic Lead to Positive Changes in Urology Residency? 96
Fibronectin (FN), epidermal growth factor-receptor (EGF-R) and heparin-binding epidermal growth factor-like (HB-EGF) urinary expressions and topical toxicity of adjuvant intravesical therapy for non muscle invasive bladder cancer (NMI-BC) 95
CORSO Carcinoma vescicale non muscolo invasivo : qualità del trattamento endoscopico 95
Does Smoking Cessation at Primary Diagnosis Reduce the Recurrence Risk of Nonmuscle-Invasive Bladder Cancer? Results of a Prospective Study 95
Recurrence and progression according to stage at re-TUR in t1g3 bladder cancer patients treated with BCG: Not as bad as previously thought 95
TUR AND ADJUVANT INTRAVESCICAL CHEMOTHERAPY IN T1G3 BLADDER TUMORS. RECURRENCE, PROGRESSION AND SURVIVAL IN 137 SELECTED PATIENTS FOLLOWED UP TO 20 YEARS. 94
Environmental factors in superficial bladder cancer. Preliminary report of a prospective study 94
Fumo, risorsa idrica ed altri fattori di rischio nel carcinoma vescicale superficiale 94
Peyronie’s disease: Cytokines genes expression in tunica albuginea 94
Correlation between clinical response and urinary interleukin levels using different doses and intravesical administration schedules of interferon-alpha-2b combined with epirubicin: a pilot study 94
Predictors of oncological outcomes in T1G3 patients treated with BCG who undergo radical cystectomy 94
Correlation between chronic prostatitis syndrome and pelvic venous disease. A survey of 2554 urologic outpatients 94
Fumo di sigaretta e risorsa idrica in pazienti affetti da carcinoma vescicale superficiale. XV Congresso Nazionale SIUro, Giardini Naxos 3-6 novembre 2005. 1. 93
Chemioterapia adiuvante e fattori di rischio ambientale nel carcinoma vescicale superficiale a medio rischio di recidiva. Uno studio prospettico randomizzato del Gruppo Studio Tumori Urologici (GSTU). 93
Single dose prulifloxacina can improve BCG tollerability 93
La p53 nel tumore vescicale superficiale (Ta-T1, G1-3) 92
Plasma levels of angiogenetic markers in men candidate to prostate biopsy 92
ESTRAMUSTINA FOSFATO VS ASSOCIAZIONE A BASSA DOSE DI ESTRAMUSTINA FOSFATO E ETOPOSIDE NEL CARCINOMA PROSTATICO ORMONOREFRATTARIO (HRPC). STUDIO RANDOMIZZATO DI FASE II DEL GRUPPO STUDI TUMORI UROLOGICI (GSTU) 91
Totale 12.199
Salva come PNG Salva come JPEG
Categoria #
all - tutte 83.771
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 83.771
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.841 0 0 0 0 0 650 526 303 495 289 362 216
2020/20212.847 134 243 190 257 253 163 268 149 317 223 277 373
2021/20222.688 126 575 61 140 150 115 73 142 332 331 108 535
2022/20233.773 418 549 89 334 406 498 229 238 801 21 137 53
2023/20241.744 71 239 171 180 153 358 153 126 11 21 75 186
2024/20251.269 138 218 199 370 204 140 0 0 0 0 0 0
Totale 22.595